Mitochondrial Neuroprotection in Traumatic Brain Injury: Rationale and Therapeutic Strategies

ISSN: 1996-3181 (Online)
ISSN: 1871-5273 (Print)


Volume 13, 10 Issues, 2014


Download PDF Flyer




CNS & Neurological Disorders - Drug Targets

Formerly: Current Drug Targets - CNS & Neurological Disorders

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 51st of 261 in Pharmacology & Pharmacy
  • 78th of 252 in Neurosciences

Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Stephen D. Skaper
Department of Pharmaceutical and Pharmacological Sciences
University of Padova
Padova
Italy


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 3.769
5 - Year: 3.923

Mitochondrial Neuroprotection in Traumatic Brain Injury: Rationale and Therapeutic Strategies

Author(s): Shoji Yokobori, Anna T. Mazzeo, Shyam Gajavelli and Malcolm R. Bullock

Affiliation: Department of Neurosurgery, University of Miami Miller School of Medicine, Lois Pope LIFE Center, Room 3-20, 1095 NW 14th Terrace, Miami, FL 33136, USA.

Abstract

Traumatic brain injury (TBI) is still the worldwide, leading cause of mortality and morbidity in young adults. The prognosis of TBI patients is strongly affected by secondary brain damage including mitochondrial dysfunctions. In many basic and clinical studies, mitochondrial dysfunctions, including the opening of mitochondrial permeability transition (mPT) pore, and treatments including cyclosporine A (CsA) have been studied. These evidences suggest an important role for mitochondria as therapeutic targets for neuroprotection after TBI.

This review summarizes the data about normal and pathological mitochondrial function after TBI, TBI pathobiology relating to mitochondrial dysfunction and therapeutic strategies including drug treatment. This review also mentioned about glucose, lactate, and pyruvate metabolisms in TBI, including the "astrocyte-neuron lactate shuttle (ANLS)" hypothesis. Mitochondrial pathophysiology in TBI is still unclear.

Thus, the pharmacological treatment in TBI patient is still challenging. This review could help further understanding of this topic. Hopefully, this could help further development and innovation for drug therapies in TBI.


Keywords: Apoptosis, astrocyte-neuron lactate shuttle, cyclosporine A, mitochondrial dysfunction, mitochondrial permeability transition pore, secondary brain injury, traumatic brain injury.

Purchase Online Rights and Permissions

Article Details

Volume: 13
Issue Number: 4
First Page: 606
Last Page: 619
Page Count: 14
DOI: 10.2174/187152731304140702112805
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science